{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T21:02:43Z","timestamp":1775163763827,"version":"3.50.1"},"reference-count":140,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T00:00:00Z","timestamp":1653696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PT national funds (FCT\/MCTES, Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia and Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior)","award":["UIDB\/50006\/2020"],"award-info":[{"award-number":["UIDB\/50006\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The complexity, and the diversity of the different types of cancers allied to the tendency to form metastasis make treatment efficiency so tricky and often impossible due to the advanced stage of the disease in the diagnosis. In recent years, due to tremendous scientific breakthroughs, we have witnessed exponential growth in the elucidation of mechanisms that underlie carcinogenesis and metastasis. The development of more selective therapies made it possible to improve cancer treatment. Although interdisciplinary research leads to encouraging results, scientists still have a long exploration journey. RNA technology represents a promise as a therapeutic intervention for targeted gene silencing in cancer, and there are already some RNA-based formulations in clinical trials. However, the use of RNA as a therapeutic tool presents severe limitations, mainly related to its low stability and poor cellular uptake. Thus, the use of nanomedicine employing nanoparticles to encapsulate RNA may represent a suitable platform to address the major challenges hampering its therapeutic application. In this review, we have revisited the potential of RNA and RNA-associated therapies to fight cancer, also providing, as support, a general overview of nanoplatforms for RNA delivery.<\/jats:p>","DOI":"10.3390\/cancers14112677","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:50:51Z","timestamp":1653814251000},"page":"2677","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Nanomedicine for the Delivery of RNA in Cancer"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5435-1218","authenticated-orcid":false,"given":"Michele","family":"Ghidini","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}]},{"given":"Sandra G.","family":"Silva","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal"}]},{"given":"Jessica","family":"Evangelista","sequence":"additional","affiliation":[{"name":"Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, Largo F. Vito 1, 00168 Rome, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8967-6642","authenticated-orcid":false,"given":"Maria Lu\u00edsa C.","family":"do Vale","sequence":"additional","affiliation":[{"name":"LAQV\/REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2209-7483","authenticated-orcid":false,"given":"Ammad Ahmad","family":"Farooqi","sequence":"additional","affiliation":[{"name":"Institute of Biomedical and Genetic Engineering (IBGE), Islamabad 44000, Pakistan"}]},{"given":"Marina","family":"Pinheiro","sequence":"additional","affiliation":[{"name":"REQUIMTE, University of Porto, 4169-007 Porto, Portugal"},{"name":"ICVS, Life and Health Sciences Research Institute, School of Medicine, University of Minho, 4710-057 Braga, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nchembio839","article-title":"RNAi therapeutics: A potential new class of pharmaceutical drugs","volume":"2","author":"Bumcrot","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"109997","DOI":"10.1016\/j.biopha.2020.109997","article-title":"RNA-based pharmacotherapy for tumors: From bench to clinic and back","volume":"125","author":"Liang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/1743-422X-7-248","article-title":"Selective gene silencing by viral delivery of short hairpin RNA","volume":"7","author":"Sliva","year":"2010","journal-title":"Virol. J."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pinel, K., Diver, L.A., White, K., McDonald, R.A., and Baker, A.H. (2019). Substantial Dysregulation of miRNA Passenger Strands Underlies the Vascular Response to Injury. Cells, 8.","DOI":"10.3390\/cells8020083"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi therapeutic and its innovative biotechnological evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-Targeted Therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1038\/mtna.2013.14","article-title":"Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer","volume":"2","author":"Wu","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1038\/mtna.2015.5","article-title":"Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer","volume":"4","author":"Hiraki","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2147\/IJN.S158290","article-title":"Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy","volume":"13","author":"Li","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Liu, A.Q., Ge, L.Y., Lu, X.L., Luo, X.L., Cai, Y.L., Ye, X.Q., and Geng, F.F. (2014). Silencing of the hTERT gene by shRNA inhibits colon cancer SW480 cell growth in vitro and in vivo. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107019"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-015-0055-3","article-title":"Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results","volume":"3","author":"Amin","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/mt.2015.138","article-title":"mRNA: Fulfilling the Promise of Gene Therapy","volume":"23","author":"Weissman","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA Versus miRNA as Therapeutics for Gene Silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Hoecke","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/17425247.2019.1669558","article-title":"Lipid-based nanoparticle formulations for small molecules and RNA drugs","volume":"16","author":"Ickenstein","year":"2019","journal-title":"Exp. Opin. Drug Deliv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.matt.2020.09.020","article-title":"Nanomaterials for Therapeutic RNA Delivery","volume":"3","author":"Han","year":"2020","journal-title":"Matter"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1208\/s12248-009-9096-1","article-title":"Targeted Delivery Systems for Oligonucleotide Therapeutics","volume":"11","author":"Yu","year":"2009","journal-title":"AAPS J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In vivo delivery of miRNAs for cancer therapy: Challenges and strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","article-title":"The many pathways of RNA degradation","volume":"136","author":"Houseley","year":"2009","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17056","DOI":"10.1038\/natrevmats.2017.56","article-title":"Tools for translation: Non-viral materials for therapeutic mRNA delivery","volume":"2","author":"Hajj","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5281","DOI":"10.1007\/s12274-018-2146-1","article-title":"Biomedical applications of mRNA nanomedicine","volume":"11","author":"Xiong","year":"2018","journal-title":"Nano Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2000099","DOI":"10.1002\/adtp.202000099","article-title":"Nanoplatforms for mRNA Therapeutics","volume":"4","author":"Meng","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_27","first-page":"1486","article-title":"Synthesis and properties of mRNAs containing the novel \u201canti-reverse\u201d cap analogs 7-methyl(3\u2032-O-methyl)GpppG and 7-methyl (3\u2032-deoxy)GpppG","volume":"7","author":"Stepinski","year":"2001","journal-title":"RNA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00216-017-0840-6","article-title":"Poly A tail length analysis of in vitro transcribed mRNA by LC-MS","volume":"410","author":"Beverly","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12015-018-9805-1","article-title":"Optimization of Synthetic mRNA for Highly Efficient Translation and its Application in the Generation of Endothelial and Hematopoietic Cells from Human and Primate Pluripotent Stem Cells","volume":"14","author":"Suknuntha","year":"2018","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1182\/blood.V87.12.5314.bloodjournal87125314","article-title":"The stability of human beta-globin mRNA is dependent on structural determinants positioned within its 3\u2032 untranslated region","volume":"87","author":"Russell","year":"1996","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Chung, B.K., and Lee, D.Y. (2012). Computational codon optimization of synthetic gene for protein expression. BMC Syst. Biol., 6.","DOI":"10.1186\/1752-0509-6-134"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Muramatsu","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mirzaei, S., Gholami, M.H., Ang, H.L., Hashemi, F., Zarrabi, A., Zabolian, A., Hushmandi, K., Delfi, M., Khan, H., and Ashrafizadeh, M. (2021). Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells, 10.","DOI":"10.3390\/cells10123348"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/35038533","article-title":"Gene therapy: Trials and tribulations","volume":"1","author":"Somia","year":"2000","journal-title":"Nat. Rev. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/bjp.2008.349","article-title":"Viral vectors: From virology to transgene expression","volume":"157","author":"Bouard","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","article-title":"Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms","volume":"11","author":"Bessis","year":"2004","journal-title":"Gene Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sainz-Ramos, M., Gallego, I., Villate-Beitia, I., Zarate, J., Maldonado, I., Puras, G., and Pedraz, J.L. (2021). How Far Are Non-Viral Vectors to Come of Age and Reach Clinical Translation in Gene Therapy?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147545"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles\u2500From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jconrel.2010.07.124","article-title":"mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers","volume":"147","author":"Rejman","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/ar300048p","article-title":"Lipid-Based Nanoparticles for siRNA Delivery in Cancer Therapy: Paradigms and Challenges","volume":"45","author":"Fonseca","year":"2012","journal-title":"Acc. Chem. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1021\/mp2002076","article-title":"MicroRNA delivery by cationic lipoplexes for lung cancer therapy","volume":"8","author":"Wu","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","article-title":"Toxicity of cationic lipids and cationic polymers in gene delivery","volume":"114","author":"Lv","year":"2006","journal-title":"J. Control. Release"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s00262-005-0064-z","article-title":"Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor\/self antigen","volume":"55","author":"Hess","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2017.09.041","article-title":"Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA","volume":"266","author":"Verbeke","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s13346-013-0158-7","article-title":"Toxicity profiling of several common RNAi-based nanomedicines: A comparative study","volume":"4","author":"Peer","year":"2014","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1805097","DOI":"10.1002\/smll.201805097","article-title":"Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH","volume":"15","author":"Hajj","year":"2019","journal-title":"Small"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1038\/s41467-018-06936-1","article-title":"Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes","volume":"9","author":"Veiga","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/nat.2018.0734","article-title":"MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct","volume":"28","author":"Jain","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/mt.2013.124","article-title":"Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics","volume":"21","author":"Maier","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","article-title":"Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines","volume":"15","author":"Hassett","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jconrel.2005.06.014","article-title":"Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids","volume":"107","author":"Heyes","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/adma.201505822","article-title":"Bioinspired Alkenyl Amino Alcohol Ionizable Lipid Materials for Highly Potent In Vivo mRNA Delivery","volume":"28","author":"Fenton","year":"2016","journal-title":"Adv. Mater."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1606944","DOI":"10.1002\/adma.201606944","article-title":"Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes","volume":"29","author":"Fenton","year":"2017","journal-title":"Adv. Mater."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcis.2020.09.077","article-title":"Effective cytocompatible nanovectors based on serine-derived gemini surfactants and monoolein for small interfering RNA delivery","volume":"584","author":"Costa","year":"2021","journal-title":"J. Colloid Interface Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"151","DOI":"10.15171\/apb.2015.022","article-title":"Solid Lipid Nanoparticles as Efficient Drug and Gene Delivery Systems: Recent Breakthroughs","volume":"5","author":"Valizadeh","year":"2015","journal-title":"Adv. Pharm. Bull."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejpb.2008.09.015","article-title":"Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy","volume":"71","author":"Pedraz","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_67","first-page":"319","article-title":"Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects","volume":"7","author":"Muraca","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12943-019-0981-7","article-title":"Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Baldari, S., Di Rocco, G., Magenta, A., Picozza, M., and Toietta, G. (2019). Extracellular Vesicles\u2013Encapsulated MicroRNA-125b Produced in Genetically Modified Mesenchymal Stromal Cells Inhibits Hepatocellular Carcinoma Cell Proliferation. Cells, 8.","DOI":"10.3390\/cells8121560"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3389\/fonc.2019.01076","article-title":"Exosomes Derived From MicroRNA-148b-3p-Overexpressing Human Umbilical Cord Mesenchymal Stem Cells Restrain Breast Cancer Progression","volume":"9","author":"Yuan","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8108576","DOI":"10.1155\/2019\/8108576","article-title":"Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Inhibit Endometrial Cancer Cell Proliferation and Migration through Delivery of Exogenous miR-302a","volume":"2019","author":"Li","year":"2019","journal-title":"Stem Cells Int."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Gilligan, K.E., and Dwyer, R.M. (2017). Engineering Exosomes for Cancer Therapy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18061122"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Ingenito, F., Roscigno, G., Affinito, A., Nuzzo, S., Scognamiglio, I., Quintavalle, C., and Condorelli, G. (2019). The Role of Exo-miRNAs in Cancer: A Focus on Therapeutic and Diagnostic Applications. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20194687"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1478-811X-11-88","article-title":"Exosomes are natural carriers of exogenous siRNA to human cells in vitro","volume":"11","author":"Shtam","year":"2013","journal-title":"Cell Commun. Signal."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/sctm.19-0114","article-title":"Mesenchymal stromal cell-derived extracellular vesicles for regenerative therapy and immune modulation: Progress and challenges toward clinical application","volume":"9","author":"Allan","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"115004","DOI":"10.1016\/j.carbpol.2019.115004","article-title":"Advances in chitosan-based nanoparticles for oncotherapy","volume":"222","author":"Zhang","year":"2019","journal-title":"Carbohy. Polym."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jconrel.2012.03.017","article-title":"Chitosan-based drug nanocarriers: Where do we stand?","volume":"161","author":"Alonso","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"117809","DOI":"10.1016\/j.carbpol.2021.117809","article-title":"Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy","volume":"260","author":"Ashrafizadeh","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Chen, H., Cui, S., Zhao, Y., Zhang, C., Zhang, S., and Peng, X. (2015). Grafting Chitosan with Polyethylenimine in an Ionic Liquid for Efficient Gene Delivery. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121817"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Lu, H., Lv, L., Dai, Y., Wu, G., Zhao, H., and Zhang, F. (2013). Porous chitosan scaffolds with embedded hyaluronic acid\/chitosan\/plasmid-DNA nanoparticles encoding TGF-\u03b21 induce DNA controlled release, transfected chondrocytes, and promoted cell proliferation. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069950"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jconrel.2013.08.005","article-title":"Chitosan-based siRNA delivery systems","volume":"172","author":"Ragelle","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_82","first-page":"765","article-title":"Recent advances of chitosan nanoparticles as drug carriers","volume":"6","author":"Wang","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.biopha.2016.06.037","article-title":"Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells","volume":"83","author":"Alinejad","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.imlet.2016.11.013","article-title":"Chitosan nanoparticles as a dual drug\/siRNA delivery system for treatment of colorectal cancer","volume":"181","author":"Sadreddini","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jphp.12593","article-title":"Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line","volume":"68","author":"Siahmansouri","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/jgm.773","article-title":"Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives","volume":"7","author":"Neu","year":"2005","journal-title":"J. Gene Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/jgm.696","article-title":"Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis","volume":"7","author":"Akinc","year":"2005","journal-title":"J. Gene Med."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Johler, S.M., Rejman, J., Guan, S., and Rosenecker, J. (2015). Nebulisation of IVT mRNA Complexes for Intrapulmonary Administration. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137504"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s13346-020-00725-4","article-title":"Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates","volume":"10","author":"Tan","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jconrel.2016.12.005","article-title":"Self-aggregating 1.8 kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides","volume":"246","author":"Chiper","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3109\/10717544.2015.1038856","article-title":"Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA","volume":"23","author":"Zhao","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2012.09.030","article-title":"Dendrimers in biomedical applications\u2014reflections on the field","volume":"64","author":"Svenson","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1016\/j.biomaterials.2011.12.045","article-title":"Gene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors","volume":"33","author":"Shan","year":"2012","journal-title":"Biomaterials"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1039\/C1CS15242D","article-title":"Multifunctional dendritic polymers in nanomedicine: Opportunities and challenges","volume":"41","author":"Khandare","year":"2012","journal-title":"Chem. Soc. Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1039\/C4NR04759A","article-title":"Promoting siRNA delivery via enhanced cellular uptake using an arginine-decorated amphiphilic dendrimer","volume":"7","author":"Liu","year":"2015","journal-title":"Nanoscale"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1039\/b9nj00609e","article-title":"Dendritic magnetite nanocarriers for drug delivery applications","volume":"34","author":"Chandra","year":"2010","journal-title":"New J. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1039\/c1jm11460c","article-title":"Dendrimer modified magnetic iron oxide nanoparticle\/DNA\/PEI ternary magnetoplexes: A novel strategy for magnetofection","volume":"21","author":"Liu","year":"2011","journal-title":"J. Mater. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"8156","DOI":"10.1158\/0008-5472.CAN-06-4762","article-title":"Dendrimer-modified magnetic nanoparticles enhance efficiency of gene delivery system","volume":"67","author":"Pan","year":"2007","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1039\/B612972B","article-title":"Improved biocompatibility of surface functionalized dendrimer-entrapped gold nanoparticles","volume":"3","author":"Shi","year":"2006","journal-title":"Soft Matter"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/smll.200700054","article-title":"Dendrimer-entrapped gold nanoparticles as a platform for cancer-cell targeting and imaging","volume":"3","author":"Shi","year":"2007","journal-title":"Small"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Pinelli, F., Perale, G., and Rossi, F. (2020). Coating and Functionalization Strategies for Nanogels and Nanoparticles for Selective Drug Delivery. Gels, 6.","DOI":"10.3390\/gels6010006"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8564","DOI":"10.1021\/cr500131f","article-title":"Biodegradable Polymer Nanogels for Drug\/Nucleic Acid Delivery","volume":"115","author":"Li","year":"2015","journal-title":"Chem. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.msec.2015.11.041","article-title":"New progress and prospects: The application of nanogel in drug delivery","volume":"60","author":"Zhang","year":"2016","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jconrel.2018.02.036","article-title":"Bioreduction-ruptured nanogel for switch on\/off release of Bcl2 siRNA in breast tumor therapy","volume":"292","author":"Li","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-5173(02)00452-0","article-title":"Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery","volume":"250","author":"Roy","year":"2003","journal-title":"Int. J. Pharm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2011.10.020","article-title":"Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor","volume":"158","author":"Li","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1021\/mp300152v","article-title":"Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner","volume":"9","author":"Yang","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jconrel.2009.11.008","article-title":"Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery","volume":"142","author":"Li","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2174\/1389201014666131226145441","article-title":"A mini review of biodegradable calcium phosphate nanoparticles for gene delivery","volume":"14","author":"Xie","year":"2013","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ymthe.2017.11.009","article-title":"mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma","volume":"26","author":"Wang","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"10644","DOI":"10.1021\/la0513712","article-title":"Biocompatibility of Gold Nanoparticles and Their Endocytotic Fate Inside the Cellular Compartment: A Microscopic Overview","volume":"21","author":"Shukla","year":"2005","journal-title":"Langmuir"},{"key":"ref_112","unstructured":"Shah, M.R., Imran, M., and Ullah, S. (2020). Chapter 4\u2014Gold nanoparticles in cancer diagnosis and therapy. Metal Nanoparticles for Drug Delivery and Diagnostic Applications, Elsevier."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Mendes, R., Fernandes, A.R., and Baptista, P.V. (2017). Gold Nanoparticle Approach to the Selective Delivery of Gene Silencing in Cancer\u2014The Case for Combined Delivery?. Genes, 8.","DOI":"10.3390\/genes8030094"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.biomaterials.2012.10.023","article-title":"A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells","volume":"34","author":"Ghosh","year":"2013","journal-title":"Biomaterials"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nano.2008.04.003","article-title":"Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues","volume":"4","author":"Foldvari","year":"2008","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.addr.2013.10.003","article-title":"Carbon nanotubes as vectors for gene therapy: Past achievements, present challenges and future goals","volume":"65","author":"Bates","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"12492","DOI":"10.1021\/ja053962k","article-title":"Functionalization of Carbon Nanotubes via Cleavable Disulfide Bonds for Efficient Intracellular Delivery of siRNA and Potent Gene Silencing","volume":"127","author":"Kam","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bbrc.2008.02.072","article-title":"Functionalization of carbon nanotubes enables non-covalent binding and intracellular delivery of small interfering RNA for efficient knock-down of genes","volume":"369","author":"Krajcik","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1158\/1078-0432.CCR-05-2831","article-title":"Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth","volume":"12","author":"Zhang","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/cmdc.200700329","article-title":"Targeted RNA Interference of Cyclin A2 Mediated by Functionalized Single-Walled Carbon Nanotubes Induces Proliferation Arrest and Apoptosis in Chronic Myelogenous Leukemia K562 Cells","volume":"3","author":"Wang","year":"2008","journal-title":"ChemMedChem"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/smll.200801572","article-title":"Antitumor Activity and Prolonged Survival by Carbon-Nanotube-Mediated Therapeutic siRNA Silencing in a Human Lung Xenograft Model","volume":"5","author":"Podesta","year":"2009","journal-title":"Small"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1096\/fj.09-141036","article-title":"Enhanced cellular internalization and gene silencing with a series of cationic dendron-multiwalled carbon nanotube:siRNA complexes","volume":"24","author":"Toma","year":"2010","journal-title":"FASEB J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1021\/cm0011559","article-title":"A New Property of MCM-41: Drug Delivery System","volume":"13","year":"2001","journal-title":"Chem. Mater."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/smll.200901966","article-title":"Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells","volume":"6","author":"Hom","year":"2010","journal-title":"Small"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.addr.2008.03.012","article-title":"Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers","volume":"60","author":"Slowing","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/adfm.201404629","article-title":"Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer","volume":"25","author":"Ngamcherdtrakul","year":"2015","journal-title":"Adv. Funct. Mater."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7150\/thno.8263","article-title":"Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics","volume":"4","author":"Shen","year":"2014","journal-title":"Theranostics"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Tivnan, A., Orr, W.S., Gubala, V., Nooney, R., Williams, D.E., McDonagh, C., Prenter, S., Harvey, H., Domingo-Fern\u00e1ndez, R., and Bray, I.M. (2012). Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038129"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"R167","DOI":"10.1088\/0022-3727\/36\/13\/201","article-title":"Applications of magnetic nanoparticles in biomedicine","volume":"36","author":"Pankhurst","year":"2003","journal-title":"J. Phys. D Appl. Phys."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1016\/j.biomaterials.2004.10.012","article-title":"Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications","volume":"26","author":"Gupta","year":"2005","journal-title":"Biomaterials"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"17761","DOI":"10.1039\/C8NR04254C","article-title":"Magnetic nanoparticles loaded with functional RNA nanoparticles","volume":"10","author":"Halman","year":"2018","journal-title":"Nanoscale"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.addr.2011.08.002","article-title":"Magnetically enhanced nucleic acid delivery. Ten years of magnetofection\u2014Progress and prospects","volume":"63","author":"Plank","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.2147\/IJN.S137245","article-title":"Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer","volume":"12","author":"Luo","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Rai, R., Alwani, S., and Badea, I. (2019). Polymeric Nanoparticles in Gene Therapy: New Avenues of Design and Optimization for Delivery Applications. Polymers, 11.","DOI":"10.3390\/polym11040745"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Kus-Li\u015bkiewicz, M., Fickers, P., and Ben Tahar, I. (2021). Biocompatibility and Cytotoxicity of Gold Nanoparticles: Recent Advances in Methodologies and Regulations. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222010952"},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Arias, L.S., Pessan, J.P., Vieira, A.P.M., Lima, T.M.T.d., Delbem, A.C.B., and Monteiro, D.R. (2018). Iron Oxide Nanoparticles for Biomedical Applications: A Perspective on Synthesis, Drugs, Antimicrobial Activity, and Toxicity. Antibiotics, 7.","DOI":"10.3390\/antibiotics7020046"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.2016.34.15_suppl.2547","article-title":"A phase I\/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC)","volume":"34","author":"Demeure","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_138","first-page":"747-e218","article-title":"An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma","volume":"24","author":"Lim","year":"2019","journal-title":"Oncologist"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Thi, T.T.H., Suys, E.J.A., Lee, J.S., Nguyen, D.H., Park, K.D., and Truong, N.P. (2021). Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9040359"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"11006","DOI":"10.1200\/jco.2015.33.15_suppl.11006","article-title":"Safety and activity of DCR-MYC, a first-in-class Dicer-substrate small interfering RNA (DsiRNA) targeting MYC, in a phase I study in patients with advanced solid tumors","volume":"33","author":"Tolcher","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2677\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:22Z","timestamp":1760138422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,28]]},"references-count":140,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112677"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112677","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,28]]}}}